Lyell Immunopharma, Inc.LYELNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank17
3Y CAGR-10.9%
5Y CAGR-2.6%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-10.9%/yr
Annual compound
5Y CAGR
-2.6%/yr
Recent deceleration
Percentile
P17
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $192.27M | -46.4% |
| 2024 | $358.82M | +45.2% |
| 2023 | $247.14M | -9.1% |
| 2022 | $271.74M | +20.5% |
| 2021 | $225.43M | +2.6% |
| 2020 | $219.69M | +113.8% |
| 2019 | $102.75M | - |